Navigation Links
CEL-SCI Presents Long-Term Cancer Survival Data With Multikine

(FDA) to proceed to a Phase III clinical trial with Multikine earlier this year. The same treatment regimen that was used in CEL-SCI's final Phase II trial will be used in the upcoming Phase III trial that CEL-SCI will undertake since the results obtained in the final Phase II trial are thought to be indicative of the results one might expect in any Phase III trial of Multikine. The Phase III trial is designed to demonstrate a 10% increase in overall survival of patients treated with adjuvant Multikine therapy versus those treated only with the current standard of care.

Dr. Talor said, "Having shown a 33% increase in overall survival with no safety concerns in the final Phase II study, we are very hopeful that we will successfully reach the 10% increase in overall survival that is the primary endpoint of our Phase III trial. To further enhance the probability of meeting our primary endpoint, we are over-enrolling the study."

Documented data were available for 19 of the 22 patients in the follow-up portion of this clinical trial. Of the three patients who could not be evaluated in the follow-up study, one patient was known to be alive, but failed to give informed consent, and the other two were lost to follow-up. One patient died the day after definitive surgery, unrelated to Multikine therapy.

Head & neck cancer is an aggressive cancer that affects over 500,000 - 600,000 people per annum worldwide.

CEL-SCI Corporation is developing new immune system based treatments for cancer and infectious diseases. The Company has received the go-ahead from the U.S. FDA and the Canadian Regulators to conduct a Phase III clinical trial in advanced primary head and neck cancer patients with its lead product Multikine. CEL-SCI's other products, which are currently in pre-clinical stage and have been funded with U.S. government support, have shown protection against a number of diseases in animal tests and are currently being tested against diseases a
'"/>




Page: 1 2 3

Related medicine technology :

1. CEL-SCIS CEL-1000 Shown to Significantly Enhance Immune Response Against Avian Flu Antigen in Animals
2. CEL-SCIs Cel-1000 Shown to Significantly Enhance Immune Response Against Hepatitis B Antigen in Animals
3. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
4. European Society for Medical Oncology (ESMO) Presents Data from the Clinical Trial of MediGenes Cancer-Killing Virus in Press Conference
5. Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity and Safety Profile of Quadramet at International Myeloma Workshop
6. SemBioSys Presents Positive Insulin Data at the American Diabetes Association Conference
7. Tranzyme Pharma Presents Initial Phase IIa Data for its Novel Ghrelin Agonist, TZP-101, in Patients with Diabetic Gastroparesis
8. Novagali Pharma Presents at AACO the Results of its Pivotal Phase III Clinical Trial of Vekacia in Children Suffering From Vernal Keratoconjunctivitis
9. BioLife Solutions Presents Data on CryoStor at International Society for Cellular Therapy Annual Meeting
10. Genaera Presents Preclinical Data on Trodusquemine (MSI-1436) for the Treatment of Obesity at the American Diabetes Association 67th Scientific Session
11. Elixir Pharmaceuticals Presents Preclinical Data Highlighting Its Ghrelin Antagonist Program at the American Diabetes Associations Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: CEL SCI Presents Long Term Cancer Survival Data With Multikine
(Date:1/15/2014)... YORK , January 15, 2014 ... Ltd., the exclusive worldwide distributor of highly sophisticated agro-breeding ... on January 7, 2014, the Company,s board of directors ... Weiner as its new member of the board. ...
(Date:1/15/2014)... 15, 2014  In an unprecedented effort to curb the spread of ... other transport vehicles, an advanced and portable UV germicidal lamp manufactured ... first time. In order to prevent EMS paramedics ... West Palm Beach Fire Rescue is the ...
(Date:1/15/2014)... 15, 2014 MultiCell Technologies, Inc. (OTC Bulletin Board: ... patent application concerning composition of matter, biological targets, mechanism ... cell death.  This patent application describes ... RNA molecules (VSRNAs) which interfere with the basic homeostatic ...
Breaking Medicine Technology:BreedIT (OTC: BRDT) Appoints Chemistry and Pharmaceutical Industry Expert Dr. Ben-Zion Weiner to Its Board of Directors 2BreedIT (OTC: BRDT) Appoints Chemistry and Pharmaceutical Industry Expert Dr. Ben-Zion Weiner to Its Board of Directors 3Superbugs No Longer Ride In Rescue Vehicles 2MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 2MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 3
(Date:7/9/2014)... common type of lung cancer, researchers have uncovered mutations ... forming tumors. The new knowledge may expand treatments for ... already are available or are in clinical trials. , ... The Cancer Genome Atlas (TCGA), including researchers at Washington ... School and other institutions, studied tumors from 230 patients ...
(Date:7/9/2014)... The Miriam Hospital have found that people with ... depressed have difficulty sticking to a pulmonary rehabilitation ... women, and screening and brief treatment of depression ... study and its findings are published in print ... obstructive pulmonary disease is a common and often ...
(Date:7/9/2014)... have been linked to an emerging fungal disease ... Institute for Mathematical and Biological Synthesis (NIMBioS) shows ... , In a series of mathematical models, researchers ... internal organs in frogs, could cause extinction of ... exposed to the virus every few years, a ...
(Date:7/9/2014)... 9, 2014) A retrospective study conducted by researchers ... reports that among adults with intellectual and developmental disabilities, ... of years receiving dental care increased. The findings, published ... Dentistry , may help improve interventions designed to address ... , The researchers reviewed the dental records of 107 ...
(Date:7/9/2014)... allergic diseases has risen dramatically in Western societies. One ... to microorganisms and have fewer infections than previous generations, ... study by researchers at Sahlgrenska Academy, University of Gothenburg, ... maturation of the immune system in relation to allergic ... of the Vstra Gtaland Region, half of them on ...
Breaking Medicine News(10 mins):Health News:Lung cancer study hints at new treatments 2Health News:Miriam Hospital study examines effect of depressed mood on pulmonary rehab completion 2Health News:Study predicts ranavirus as potential new culprit in amphibian extinctions 2Health News:Adults with special needs see gains, challenges with long term oral care 2Health News:Adults with special needs see gains, challenges with long term oral care 3
... Male high school athletes more likely to drink and fight ... News) -- When it comes to teaching healthy behaviors, boys, ... thought. , New research suggests that for teenage boys, participation ... and binge drinking. , Girls, on the other hand, ...
... Study finds medication works as well in certain people, ... -- People suffering from blocked renal arteries fare just ... by having the narrowed artery opened and a stent ... chronic kidney disease -- people with severe hypertension -- ...
... ... employment and networking portal for people with disabilities and renews its commitment to leading the ... ... recently passed a milestone, the one year anniversary of the launch on November 7, 2008 ...
... Announces VSO Support For Lung Cancer Legislation , ... all veterans today on Veterans Day and announces the ... veterans on lung cancer -- the leading cause of ... ) , LCA also announces that major ...
... Near 9% Unemployment Leaves More Idaho Families Struggling with ... , BOISE, Idaho, Nov. 11 As Idaho,s jobless ... the over 67,300 unemployed Idahoans finding themselves without employer benefits. ... is calling on Idaho,s Congressional delegation to set politics aside ...
... Nov. 11 Accelify is proud to announce the addition of ... of Development in the State of Florida and will also join ... Accelify, Sandra served for eight years as a member of the ... During her time in the Florida legislature, she personally sponsored ...
Cached Medicine News:Health News:Boys' Team Sports May Encourage Bad Behavior 2Health News:Boys' Team Sports May Encourage Bad Behavior 3Health News:Surgery Not Always Best for Narrowed Kidney Arteries 2Health News:Surgery Not Always Best for Narrowed Kidney Arteries 3Health News:GettingHired.com Recognizes First Year Anniversary, Renews Commitment to Helping Lead the Effort to Reduce Employment Participation Gap for People with Disabilities 2Health News:GettingHired.com Recognizes First Year Anniversary, Renews Commitment to Helping Lead the Effort to Reduce Employment Participation Gap for People with Disabilities 3Health News:Lung Cancer Alliance Salutes Veterans 2Health News:Idaho's Rising Jobless Rate Fuels State's Growing Health Care Woes 2Health News:Accelify Announces the Addition of Sandra L. Murman to its National Board of Advisors 2Health News:Accelify Announces the Addition of Sandra L. Murman to its National Board of Advisors 3
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: